Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 968 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Completed Phase 2 Interventional Results available

Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

NCT00220779
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580
View directory record Official record
Conditions
Healthy
Interventions
Ortho-Cyclen, AG200-15
Drug
Lead sponsor
Agile Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 28, 2026, 6:36 AM EDT
Recruiting Phase 4 Interventional

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970
View directory record Official record
Conditions
Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
Interventions
Acalabrutinib, Investigator's choice of treatment
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
3
States / cities
Charlotte, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Not applicable Interventional

A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss

NCT04450602
View directory record Official record
Conditions
Androgenetic Alopecia, Androgenic Alopecia, Telogen Effluvium, Thinning Hair, Hair Loss/Baldness, Hair Thinning
Interventions
ALRV5XR, ALRV5XR Shampoo, ALRV5XR Conditioner, ALRV5XR Hair Follicle Serum (Nutriment), Placebo, Placebo Shampoo, Placebo Conditioner, Placebo Hair Follicle Serum (Nutriment)
Dietary Supplement · Other
Lead sponsor
Arbor Life Labs
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 2 Interventional Results available

A Study of CIN-107 in Patients With Uncontrolled Hypertension

NCT05137002
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
CIN-107, Placebo
Drug
Lead sponsor
CinCor Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 28, 2026, 6:36 AM EDT
Withdrawn Not applicable Interventional

Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department

NCT00388739
View directory record Official record
Conditions
Asthma
Interventions
Intervention: Budesonide, Usual care: albuterol + systemic steroids
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 28, 2026, 6:36 AM EDT
Terminated Phase 3 Interventional

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

NCT04489537
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
MarzAA
Biological
Lead sponsor
Catalyst Biosciences
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Not applicable Interventional

Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)

NCT05716542
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
Physical Activity Intervention
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 28, 2026, 6:36 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia

NCT05182476
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Luvadaxistat
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

NCT05166889
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
36
States / cities
Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 6:36 AM EDT
Recruiting Not applicable Interventional

Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

NCT05642884
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Multi-modal Exercise Regimen, Dietary Guidelines
Other · Behavioral
Lead sponsor
Noha Mohamed Sharafeldin
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

NCT00385697
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Teplizumab, Placebo
Biological · Drug
Lead sponsor
MacroGenics
Industry
Eligibility
8 Years to 35 Years
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

NCT02994927
View directory record Official record
Conditions
ANCA-Associated Vasculitis
Interventions
Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
41
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

NCT03853694
View directory record Official record
Conditions
Elective Cesarean Section, Pain Management
Interventions
50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Stanford, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

NCT00263341
View directory record Official record
Conditions
Contraception
Interventions
NES/EE CVR
Combination Product
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Sedentary Time in Chronic Low Back Pain: Sedentary Intervention Using Motivational Interviewing and Technology

NCT04257539
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Intervention to Reduce Sedentary Time
Behavioral
Lead sponsor
Iowa State University
Other
Eligibility
25 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

NCT03345914
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching Placebo, Background Treatment: Topical Corticosteroids, Background Treatment: Moisturizers
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Gilbert, Arizona • Bakersfield, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 28, 2026, 6:36 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Dental Plaque and Gingivitis.

NCT07605338
View directory record Official record
Conditions
Plaque, Dental, Gingivitis
Interventions
Colgate SNaP Total 10/10, 1.5 Taurate, Colgate Great Regular Flavor Toothpaste, Flat Trimmed Extra Clean TB
Drug · Other
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Costa Mesa, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 4 Interventional Results available

ESP Block for Post Cesarean Analgesia

NCT05664958
View directory record Official record
Conditions
Cesarean Section Complications
Interventions
Erector Spinae Plane (ESP) Block, bupivacaine liposome injectable suspension, bupivacaine
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

Fesoterodine Flexible Dose Study

NCT00536484
View directory record Official record
Conditions
Overactive Bladder
Interventions
Fesoterodine, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Mobile, Alabama • Chandler, Arizona • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 28, 2026, 6:36 AM EDT
Terminated Phase 1 Interventional

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

NCT03059563
View directory record Official record
Conditions
Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 28, 2026, 6:36 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Ianalumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
22
States / cities
Anniston, Alabama • Burbank, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 28, 2026, 6:36 AM EDT
Completed Phase 3 Interventional Results available

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

NCT00975286
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Placebo, Insulin glargine, Pen auto-injector, Metformin, Thiazolidinedione (TZD)
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Mesa, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2016 · Synced Oct 28, 2026, 6:36 AM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

NCT01655407
View directory record Official record
Conditions
Thermal Injury, Deep Partial-Thickness Burn, Full-Thickness Burn
Interventions
Autologous Engineered Skin Substitute, Split-Thickness Autograft (AG)
Drug
Lead sponsor
Amarantus BioScience Holdings, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Pheonix, Arizona • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 28, 2026, 6:36 AM EDT